A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing–remitting multiple sclerosis (TIME MS)

Background: Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. Objective: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral MMF in multiple s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Remington, Gina M., Treadaway, Katherine, Frohman, Teresa, Salter, Amber, Stüve, Olaf, Racke, Michael K., Hawker, Kathleen, Agosta, Federica, Sormani, Maria Pia, Filippi, Massimo, Frohman, Elliot M.
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2010
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3002615/
https://ncbi.nlm.nih.gov/pubmed/21180632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285609355851
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados